Doxorubicin-Induced Cardiotoxicity and the Emerging Role of SGLT2 Inhibitors: From Glycemic Control to Cardio-Oncology. - Goje ID; Goje GI; Ordodi VL; Ciobotaru VG; Ivan VS; Buzaș R; Tunea O; Bojin F; Lighezan DF (Pharmaceuticals (Basel, Switzerland), 2025)